Goldman Sachs Group, Inc. (The) Reaffirms “Sell” Rating for AstraZeneca plc (AZN)

Goldman Sachs Group, Inc. (The) reaffirmed their sell rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Friday. The firm currently has a GBX 3,900 ($50.93) price objective on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on the company. Shore Capital restated a hold rating on shares of AstraZeneca plc in a research note on Thursday, July 13th. J P Morgan Chase & Co reaffirmed a neutral rating on shares of AstraZeneca plc in a report on Thursday, July 13th. Kepler Capital Markets reaffirmed a buy rating and issued a GBX 5,500 ($71.82) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Liberum Capital reaffirmed a buy rating and issued a GBX 5,500 ($71.82) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Finally, Citigroup Inc. reaffirmed a buy rating and issued a GBX 6,000 ($78.35) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of GBX 5,251.80 ($68.58).

AstraZeneca plc (LON AZN) traded up 0.58% during mid-day trading on Friday, reaching GBX 5069.00. The company had a trading volume of 1,763,249 shares. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The stock has a 50 day moving average price of GBX 5,259.89 and a 200 day moving average price of GBX 4,769.91. The company’s market capitalization is GBX 64.17 billion.

ILLEGAL ACTIVITY NOTICE: “Goldman Sachs Group, Inc. (The) Reaffirms “Sell” Rating for AstraZeneca plc (AZN)” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://sportsperspectives.com/2017/07/18/goldman-sachs-group-inc-the-reaffirms-sell-rating-for-astrazeneca-plc-azn.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply